Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease
- PMID: 29436735
- DOI: 10.1002/mds.27284
Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease
Abstract
Background: Pathological accumulation of α-synuclein, amyloid-β42 , and tau proteins in the brain is considered critical for development of various neurodegenerative diseases.
Objectives: We investigated the association between CSF levels of these biomarkers, brain structural connectivity, and the UPDRS in PD.
Methods: Diffusion tensor images and CSF biomarkers (α-synuclein, amyloid-β42 , total tau, and phosphorylated tau181) from 132 drug-naïve, nondemented PD patients and 61 healthy controls were obtained from the Parkinson's Progression Markers Initiative database. After network reconstruction of structural connectivity patterns, global interconnectivity measures (including global efficiency, clustering coefficient, and characteristic path length) and local efficiency were calculated. Network properties and CSF biomarkers were compared between PD patients and healthy controls. The association of CSF biomarkers with network properties and UPDRS-III score was investigated.
Results: Global measures (but not local efficiency) and CSF α-synuclein were significantly lower in PD patients. Global efficiency and clustering coefficient correlated positively with α-synuclein, Aβ42 , and total tau CSF levels. Furthermore, these CSF biomarkers showed no significant association with the UPDRS-III score.
Conclusions: This study examined the association of CSF biomarkers that reflect the brain pathology, with structural brain connectivity and UPDRS-III in PD. Our results revealed an association between the abnormal aggregation of α-synuclein, Aβ42 , and tau proteins and structural connectivity disruption in PD patients. In summary, a combination of structural imaging and measurement of CSF biomarkers provide a better understanding of the pathogenesis of PD. © 2018 International Parkinson and Movement Disorder Society.
Keywords: CSF biomarkers; DTI; Parkinson's disease; UPDRS; structural networks.
© 2018 International Parkinson and Movement Disorder Society.
Similar articles
-
Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.Mov Disord. 2017 Jul;32(7):1066-1073. doi: 10.1002/mds.27001. Epub 2017 May 26. Mov Disord. 2017. PMID: 28548309
-
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.JAMA Neurol. 2013 Oct;70(10):1277-87. doi: 10.1001/jamaneurol.2013.3861. JAMA Neurol. 2013. PMID: 23979011 Free PMC article.
-
Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.Neurosci Lett. 2020 Jan 10;715:134564. doi: 10.1016/j.neulet.2019.134564. Epub 2019 Nov 13. Neurosci Lett. 2020. PMID: 31733322
-
Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.J Neurochem. 2016 Oct;139 Suppl 1:290-317. doi: 10.1111/jnc.13390. Epub 2016 Feb 10. J Neurochem. 2016. PMID: 26452984 Review.
-
Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson's disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis.Neurol Sci. 2017 Nov;38(11):1953-1961. doi: 10.1007/s10072-017-3088-1. Epub 2017 Aug 14. Neurol Sci. 2017. PMID: 28808876 Review.
Cited by
-
Tau and Amyloid-β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters.Front Neurol. 2022 Feb 25;13:748599. doi: 10.3389/fneur.2022.748599. eCollection 2022. Front Neurol. 2022. PMID: 35280296 Free PMC article.
-
REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.J Neurol. 2022 Sep;269(9):4836-4845. doi: 10.1007/s00415-022-11120-z. Epub 2022 Apr 15. J Neurol. 2022. PMID: 35426534
-
Robust Ensemble Classification Methodology for I123-Ioflupane SPECT Images and Multiple Heterogeneous Biomarkers in the Diagnosis of Parkinson's Disease.Front Neuroinform. 2018 Aug 14;12:53. doi: 10.3389/fninf.2018.00053. eCollection 2018. Front Neuroinform. 2018. PMID: 30154711 Free PMC article.
-
Global Alterations of Whole Brain Structural Connectome in Parkinson's Disease: A Meta-analysis.Neuropsychol Rev. 2023 Dec;33(4):783-802. doi: 10.1007/s11065-022-09559-y. Epub 2022 Sep 20. Neuropsychol Rev. 2023. PMID: 36125651 Free PMC article. Review.
-
Disrupted Brain Structural Network Connection in de novo Parkinson's Disease With Rapid Eye Movement Sleep Behavior Disorder.Front Hum Neurosci. 2022 Jul 19;16:902614. doi: 10.3389/fnhum.2022.902614. eCollection 2022. Front Hum Neurosci. 2022. PMID: 35927996 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical